Molecular Biology Reports

, Volume 37, Issue 1, pp 81–85

Increased serum interleukin 17 in patients with systemic lupus erythematosus

Authors

  • Xue-Fei Zhao
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Hai-Feng Pan
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Hui Yuan
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Wen-Hui Zhang
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Xiang-Pei Li
    • Department of RheumatologyAnhui Provincial Hospital
  • Gui-Hong Wang
    • Department of RheumatologyAnhui Provincial Hospital
  • Guo-Cui Wu
    • Department of PharmacologyAnhui Medical University
  • Hong Su
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Fa-Ming Pan
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Wen-Xian Li
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Lian-Hong Li
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Guo-Ping Chen
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
Article

DOI: 10.1007/s11033-009-9533-3

Cite this article as:
Zhao, X., Pan, H., Yuan, H. et al. Mol Biol Rep (2010) 37: 81. doi:10.1007/s11033-009-9533-3

Abstract

Interleukin 17 (IL-17) is a Th17 cytokine associated with inflammation, autoimmunity and defense against some bacteria, it has been implicated in many chronic autoimmune diseases including psoriasis, multiple sclerosis and systemic sclerosis. However, whether IL-17 plays a role in the pathogenesis of systemic lupus erythematosus (SLE) remains unclear. In the present study, we aimed to investigate the serum IL-17 level in patients with SLE and it’s associations with disease manifestations and activity. Fifty-seven patients with SLE and 30 healthy volunteers were recruited. Serum IL-17 levels were examined by enzyme linked immunosorbent assay (ELISA). Statistic analyzes were performed by SPSS 10.01. Results show that serum IL-17 levels were significantly elevated in SLE patients as compared with normal controls. Nevertheless, no associations of serum IL-17 level with clinical and laboratory parameters were found; no significant difference regarding serum IL-17 level between SLE patients with nephritis and those without nephritis was found; no significant difference was found between Less active SLE and More active SLE; Correlation analysis between serum IL-17 levels and SLEDAI showed no association. Taken together, our results indicate increased serum IL-17 levels in SLE patients, suggesting that this cytokine may trigger the inflammatory process in SLE. However, no associations of serum IL-17 level with disease manifestations were found. Therefore, further studies are required to confirm this preliminary data.

Keywords

Interleukin 17 Systemic lupus erythematosus

Copyright information

© Springer Science+Business Media B.V. 2009